Combination of statin/vitamin ID and metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of two randomized clinical trials.

被引：0
|
作者：
de Velasco, Guillermo
Lora, David
Carretero-Gonzalez, Alberto
Martin Soberon, Maria Cruz
Sepulveda Sanchez, Juan Manuel Manuel
Lorente, David
Castellano, Daniel E.
机构：
[1] Univ Hosp 12 Octubre, Dept Med Oncol, I 12, Madrid, Spain
[2] Hosp 12 Octubre, Madrid, Spain
[3] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Hosp Prov Castellon, Dept Med Oncol, Castellon De La Plana, Spain
[6] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.6617
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6617
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] BENEFIT-RISK ANALYSIS TO SUPPORT DOSE SELECTION OF IPATASERTIB IN COMBINATION WITH ABIRATERONE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC).
    Zhu, R.
    Musib, L.
    Maslyar, D.
    Yu, W.
    Ma, H.
    Poland, B.
    Wada, R.
    Liu, Q.
    Jin, J. Y.
    Budha, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S54 - S54
  • [43] Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.
    Flaig, Thomas W.
    Smith, Matthew R.
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    Small, Eric Jay
    Shore, Neal D.
    Fizazi, Karim
    De Porre, Peter
    Kheoh, Thian
    Li, Jinhui
    Todd, Mary Beth
    Griffin, Thomas W.
    Ryan, Charles J.
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [44] Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC)
    Kim, Joseph W.
    McKay, Rana R.
    Taplin, Mary-Ellen
    Davis, Nancy B.
    Monk, Paul
    Appleman, Leonard Joseph
    Lara, Primo
    Vaishampayan, Ulka N.
    Zhang, Jingsong
    Paul, Asit K.
    Bubley, Glenn
    Van Allen, Eliezer Mendel
    Huang, Ying
    Zhang, Zhenwei
    Loda, Massimo
    Shapiro, Geoffrey
    LoRusso, Patricia
    Ivy, S. Percy
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [46] ABIRATERONE AND ENZALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) POST CHEMOTHERAPY: AN INDIRECT COMPARISON AND BUDGET IMPACT ANALYSIS
    Li, T.
    Thompson, M.
    Todd, M.
    Yu, M.
    Kheoh, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A394 - A394
  • [47] Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial
    Kimura, Go
    Yonese, Junji
    Fukagai, Takashi
    Kamba, Tomomi
    Nishimura, Kazuo
    Nozawa, Masahiro
    Mansbach, Hank
    Theeuwes, Ad
    Beer, Tomasz M.
    Tombal, Bertrand
    Ueda, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 395 - 403
  • [48] Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: An observational study in the Netherlands
    Westgeest, H. M.
    Kuppen, M.
    van den Eertwegh, A. J. M.
    Van Moorselaar, J.
    Mehra, N.
    van Oort, I.
    van den Bergh, A. C. M.
    Coenen, J. L.
    Aben, K. K. H.
    Somford, R.
    de Wit, R.
    Bergman, A.
    Lavalaye, J.
    Uyl-de Groot, C. A.
    Gerritsen, W. R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Therapeutic options in metastatic castration-resistant prostate cancer (mCRPC): A cost-effectiveness analysis.
    Zhong, Lixian
    Srinivas, Sandy
    Pon, Vickie
    Nicole Nguyen
    Frear, Meghan
    Kwan, Sherry
    Gong, Cynthia
    Malmstrom, Robert
    Loucks, Aimee
    Wilson, Leslie
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer A meta-analysis of randomized controlled trials
    Gong, Ping
    Liu, Hongjian
    Liu, Xinyu
    Zhou, Ge
    Liu, Meitian
    Yang, Xiaodi
    Xiong, Wenjing
    Wang, Qi
    Ma, Juan
    Ren, Zheng
    He, Minfu
    Zhang, Xiumin
    MEDICINE, 2018, 97 (46)
12345